
Opinion|Videos|February 10, 2025
Clinical Trial Evidence in Second-Line Treatment: Analysis of Response Criteria and Patient Selection
Author(s)Aaron T. Gerds, MD, MS, Jeanne Palmer, MD
Panelists discuss how clinical trial data inform the selection of second-line therapies for patients with myelofibrosis, focusing on response assessment criteria and identifying optimal candidates for various treatment options.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































